Cagrilintide

Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity[1][2][3].

Signaling Pathways >> GPCR/G Protein >> CGRP Receptor

Signaling Pathways >> Neuronal Signaling >> CGRP Receptor

Research Areas >> Metabolic Disease

Cagrilintide (compound 23) (0.1, 1, 3, 10, 30 nmol/kg; s.c.) reduces food intake in the rat[2]. Cagrilintide (10 nmol/kg; i.v. or s.c.) shows good pharmacokinetic parameters[2]. Animal Model: 12 weeks, 400 g Sprague Dawley male rats[2] Dosage: 0.1, 1, 3, 10, 30 nmol/kg Administration: S.c.; once for 80 h Result: Reduced food intake in the rat for several days at doses in the range of 1-10 nmol/kg. Animal Model: 12 weeks, 400 g Sprague Dawley male rats[2] Dosage: 10 nmol/kg Administration: I.v.; s.c. Result: Showed good pharmacokinetic parameters with T1/2 of 20±2, 27±3 h for i.v. and s.c., respectively.

[1]. Fletcher MM, et al. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. J Pharmacol Exp Ther. 2021 Jun;377(3):417-440.

[2]. Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021 Aug 12;64(15):11183-11194.

[3]. Dehestani B, et al. Amylin as a Future Obesity Treatment. J Obes Metab Syndr. 2021 Dec 30;30(4):320-325.